An anonymous director reports

PROMIS ANNOUNCES COMPLETION OF CONTINUANCE

Promis Neurosciences Inc. has completed its continuance from the Canada Business Corporations Act into the province of Ontario under the Business Corporations Act (Ontario) as of July 13, 2023. The continuance was approved by the corporation's shareholders with a 97.7-per-cent majority via a special resolution at the corporation's annual meeting of shareholders held on June 29, 2023. The shift will facilitate internal management functions, and is not envisioned to impact operations. The company continues to operate with its headquarters in Toronto as well as its research laboratories, under the direction of chief scientific officer Dr. Neil Cashman, in British Columbia and its U.S. office in Cambridge, Mass.

No action will be required by existing shareholders with respect to the continuance.

About Promis Neurosciences Inc.

Promis Neurosciences is a development-stage biotechnology corporation focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). The corporation's proprietary target discovery engine is based on the use of two complementary techniques. The corporation applies its thermodynamic, computational discovery platform -- Promis and Collective Coordinates -- to predict novel targets known as disease-specific epitopes on the molecular surface of misfolded proteins. Using this unique approach, the corporation is developing novel antibody therapeutics for AD, ALS and MSA. Promis is headquartered in Toronto, Ont., Canada, with offices in Cambridge, Mass., United States.

We seek Safe Harbor.